you make a good point - an OTC biotech fits in the
Post# of 148280
The problem is that (and maybe it was just my problem) - i had perceived the company to have been somewhat "de-risked" by hitting the primary endpoints in the HIV trial. In other words, at the very least, we do a couple billion in revenue and trade at $10 billion market cap. Don't know if others had felt that way - but that lead me to invest more in this company than i would have otherwise.